title: Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells.
abstract: Experiments were performed to investigate the impact of didanosine (ddI), lamivudine (3TC), and stavudine (d4T) on cell survival and mutagenicity in two reporter genes, hypoxanthine-guanine phosphoribosyltransferase (HPRT) and thymidine kinase (TK), using a cell cloning assay for assessing the effects of individual nucleoside analogs (NRTIs)/drug combinations in human TK6 B-lymphoblastoid cells. Three-day treatments with 0, 33, 100, or 300 microM ddI, 3TC, or ddI-3TC produced positive trends for increased HPRT and TK mutant frequencies. While dose-related trends were too small to reach significance after treatments with d4T or d4T-3TC, pairwise comparisons with control cells indicated that exposure to 100 microM d4T or d4T-3TC caused significant elevations in HPRT mutants. Measurements of mutagenicity in cells exposed to d4T (or d4T-3TC) were complicated by the cytotoxicity of this NRTI. Enhanced increases in mutagenic responses to combined NRTI treatments, compared with single drug treatments, occurred as additive to synergistic effects in the HPRT gene of cells exposed to 100 microM ddI-3TC or 100 microM d4T-3TC, and in the TK gene of cells exposed to 100 or 300 microM ddI-3TC. Comparisons of these data to mutagenicity studies of other NRTIs in the same system (Meng Q et al. [2000c]: Proc Natl Acad Sci USA 97:12667-126671; Torres SM et al. [2007]: Environ Mol Mutagen) indicate that the relative mutagenic potencies for all drugs tested to date are: AZT-ddI > ddI-3TC > AZT-3TC congruent with AZT-3TC-ABC (abacavir) > AZT >/=ddI > d4T-3TC > 3TC > d4T >/= ABC. These collective data suggest that all NRTIs with antiviral activity against HIV-1 may cause host cell DNA damage and mutations, and impose a cancer risk.
authors.affiliation: Lovelace Respiratory Research Institute, Albuquerque, New Mexico, USA.
authors.forename: Meghan M
authors.initials: MM
authors.lastname: Carter
authors.forename: Salina M
authors.initials: SM
authors.lastname: Torres
authors.forename: Dennis L
authors.initials: DL
authors.lastname: Cook
authors.forename: Consuelo L
authors.initials: CL
authors.lastname: McCash
authors.forename: Mia
authors.initials: M
authors.lastname: Yu
authors.forename: Vernon E
authors.initials: VE
authors.lastname: Walker
authors.forename: Dale M
authors.initials: DM
authors.lastname: Walker
mesh_terms: D019380:Anti-HIV Agents / Q000633:toxicity; D002460:Cell Line; D016049:Didanosine / Q000633:toxicity*; D004347:Drug Interactions; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics; D019259:Lamivudine / Q000633:toxicity*; D009152:Mutagenicity Tests; D009153:Mutagens / Q000633:toxicity*; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000633:toxicity*; D018119:Stavudine / Q000633:toxicity*; D013937:Thymidine Kinase / Q000235:genetics
chemical_list: D019380:Anti-HIV Agents; D009153:Mutagens; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D018119:Stavudine; D007041:Hypoxanthine Phosphoribosyltransferase; D013937:Thymidine Kinase; D016049:Didanosine